A) Biological onset (inception), pre-clinical and clinical phases of the natural history of a disease. a) Biological onset (inception), pre-clinical and.

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

Evolution of ventilatory settings in randomised controlled trials investigating noninvasive ventilation in stable or post-exacerbation chronic obstructive.

P. Melin Clinical Microbiology and Infection

Least squares (LS) mean change from baseline (95% CI) in trough forced expiratory volume in 1 s (FEV1) according to chronic obstructive pulmonary disease.

Echocardiography view

The influence of noninvasive ventilation (NIV) on the delicate balance between increased load and decreased capacity of the respiratory system in severe.

Correlation of excessive reactive oxygen species (ROS) production to clinical disease severity. Correlation of excessive reactive oxygen species (ROS)

The EASI model structured around four modules (exposure (top left), activity (bottom left), severity (top right) and impact (bottom right)), each of which.

Consolidated Standards of Reporting Trials (CONSORT) diagram of patients enrolled in the study. #: Two pre-screen/screen failures were erroneously randomised,

Flowchart for calculating the relative risk (RR) for cancer X and lung cancer (LC). Flowchart for calculating the relative risk (RR) for cancer X and lung.

Kaplan–Meier curves of 12-month survival after an index chronic obstructive pulmonary disease-related hospitalisation according to level of moderate and.

Dried blood spot for therapeutic drug monitoring. a).

Prevalence of true-positive, false-negative and false-positive cases of chronic obstructive pulmonary disease identified with the fixed-limit Global Initiative.

Forced expiratory volume in 1 s (FEV1) results in the RECOVER trial.

A) CT scan of patient number 1, before pembrolizumab; b) CT scan of patient number 1, after 11 pembrolizumab infusions; c) CT scan of patient number 1,

Empirical antibiotic treatment algorithm for hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP). Empirical antibiotic treatment algorithm.

Survival without tracheostomy

Effects of reslizumab on: (a) clinical asthma exacerbation (CAE) rates; (b) rates of clinical asthma exacerbation requiring oral corticosteroids (OCS);

Influence of do-not-resuscitate (DNR) order specification on overall survival in chronic obstructive pulmonary disease (COPD) patients (log rank test p

Kaplan–Meier curve for the time until the development of lung cancer in patients with idiopathic pulmonary fibrosis. Kaplan–Meier curve for the time until.

A) Exhaled nitric oxide fraction (FeNO) before and after 9 weeks of treatment; b) percentage change in forced expiratory volume in 1 s (FEV1) following.

Distribution of lower extremity artery disease (LEAD) Fontaine stages over the combined chronic obstructive pulmonary disease (COPD) Global Initiative.

Bland–Altman plot of slopes of measurement 1 versus 2

Least squares (LS) mean change from baseline (95% CI) in St George's Respiratory Questionnaire (SGRQ) Total score according to exacerbation history (intent-to-treat.

Measurement of the frenulum using the commercially available Quick Tongue Tie Assessment Kit (Neo Health Services Inc., Coconut Creek, FL, USA). a) Normal.

Cluster diagram for four patient pairs with genotyped strains sharing the same sequence typing (ST). Cluster diagram for four patient pairs with genotyped.

Effects of reslizumab on asthma quality of life questionnaire (AQLQ) score in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Effects of reslizumab.

Decision tree of the BLUE protocol.

Schematic representation of the potential clinical courses of idiopathic pulmonary fibrosis. Schematic representation of the potential clinical courses.

Venn diagram showing the overlap between the various chronic obstructive pulmonary disease (COPD) diagnoses: self-reported physician-diagnosed, fixed ratio.

Different lung function trajectories potentially relevant for the understanding of the natural history of chronic obstructive pulmonary disease. a) Lung.

Forest plot displaying the effect estimates comparing azithromycin and placebo treatment in subgroups defined by above (>0.39 ng·mL−1) or below (

A white elephant or the elephant in the room

Swimmer plots showing post-nivolumab progression-free survival for the three main drugs studied according to the line of treatment in which they were received.

Least squares (LS) mean change from baseline (95% CI) in St George's Respiratory Questionnaire (SGRQ) Total score according to chronic obstructive pulmonary.

Kaplan–Meier curves of long-term survival in young (

Health-related quality of life measured by the RAND 36-Item Health Survey according to modified Medical Research Council (mMRC) dyspnoea scale groups.

Ethnic density distributions (%) by Middle Super Output Area mapped across south and east London for general practitioner-registered populations: a) Bangladeshi,

An audit of the post-hospitalisation pulmonary rehabilitation pathway in a northwest London hospital. An audit of the post-hospitalisation pulmonary rehabilitation.

The symptomatic threshold for exacerbations and how treatments are likely to reduce the rate of exacerbations. a) Variations over time (solid line) and.

Most frequent words and phrases based on user comments about the registry. Most frequent words and phrases based on user comments about the registry. Word.

Least squares (LS) mean change from baseline (95% CI) in trough forced expiratory volume in 1 s (FEV1) according to exacerbation history (intent-to-treat.

Reducing antibiotic use in influenza: challenges and rewards

Measured maximal oxygen consumption (V′O2peak) in a) 58 men and b) 41 women, aged >70 years and free of chronic diseases. Measured maximal oxygen consumption.

Systems biology as a tool to improve idiopathic pulmonary fibrosis (IPF) treatment effectiveness. Systems biology as a tool to improve idiopathic pulmonary.

a) Mortality per time point (p<0

Specific therapeutic and prophylactic interventions to consider in different taxonomic groups of chronic obstructive pulmonary diseases (COPDs). Specific.

Venn diagram showing the overlap between the various spirometric definitions of airway obstruction and respiratory symptoms. **: p

Schematic overview of the suggested pharmacological management of chronic obstructive pulmonary disease (COPD). Schematic overview of the suggested pharmacological.

A family-based pulmonary rehabilitation (PR) programme enhanced the coping resources of the families of chronic obstructive pulmonary disease patients.

The regression lines between the asynchrony index (AI) and the double true index (DTI) shown for overall data, and for mask and helmet separately. The.

Forest plot of adjusted odds ratios (with 95% confidence intervals) from multivariable multinomial logistic regression analysis (table 4), by number of.

Concordance of review article recommendations with contemporary guidelines. Concordance of review article recommendations with contemporary guidelines.

Weekly pneumococcal community-acquired pneumonia incidence rates over 5 years, with delineated school holiday periods by year. a) Year 1 (September 2008–2009).

Physician perspectives on the most useful methods for monitoring α1-antitrypsin deficiency in the clinical trial setting versus clinical practice. Physician.

Differences in a) functional residual capacity (FRC) and b) lung clearance index (LCI) when using all trials in comparison with only the first two trials.

Scatter plot of body mass index (BMI) versus forced expiratory volume in the first second (FEV1), and linear correlation lines for normal spirometry and.

Percentage of women using snus and/or cigarette smoke during pregnancy based on self-reported time for stopping from those who completed both 18-week and.

Physician perspectives on self-administration of i. v. α1-antitrypsin

Distribution of patients in the first- or second-year follow-up according to the number of acute exacerbations of chronic obstructive pulmonary disease.

Effect of omalizumab (n = 209) on a) clinically significant and b) severe exacerbation rates, compared with placebo (n = 210). #: adjustment due to a pre-study.

Forest plot from meta-analysis carried out on four studies including high-dose N-acetylcysteine (NAC) treatment a) assessing the relative risk of chronic.

Transcriptomic fingerprint of advanced idiopathic pulmonary fibrosis (IPF) lung. Transcriptomic fingerprint of advanced idiopathic pulmonary fibrosis (IPF)

Composition of the most common clusters at the a) onset of the first acute respiratory tract infection (swab A) and b) 3 weeks later (swab B) illustrated.

Scatterplots showing baseline correlation between forced expiratory volume in 1 s (FEV1) % pred and a) COPD Assessment Test (CAT), b) Clinical COPD Questionnaire.

Absolute change in forced expiratory volume in 1 s (FEV1) % pred over time in clinical trials with a) ivacaftor (IVA) in patients with at least one G551D.

Age, cohort and time period effects and weighted drift of mortality rates for chronic lower respiratory diseases for men (blue lines) and women (pink lines)

The grading system illustrated by photographic images of the larynx showing the different grades of laryngeal obstruction at the glottic and supraglottic.

Percentage of positive results by pathogen among study patients with identified pathogens. “Other” includes respiratory viruses, Stenotrophomonas, Prevotella,

Signal intensity of Mycobacterium tuberculosis lipoarabinomannan in urine of children with tuberculosis (TB) in a high TB/HIV setting by ELISA at different.

Presentation transcript:

a) Biological onset (inception), pre-clinical and clinical phases of the natural history of a disease. a) Biological onset (inception), pre-clinical and clinical phases of the natural history of a disease. Four different preventive strategies are also illustrated. Tx: treatment. b) Target population and goals of these four preventive strategies. Reproduced from https://www.med.uottawa.ca/sim/data/Prevention_e.htm Alvar Agustí, and Bartolomé Celli ERJ Open Res 2017;3:00117-2017 ©2017 by European Respiratory Society